Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa

• The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans.
• RV-001 starting dose was generally well tolerated in this open-label trial.
• RV-001 a gene-agnostic approach for RP patients.

Tokyo, Japan, February 13, 2025 - Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed at Keio University Hospital.

Phase I/II Safety, Tolerability, and Exploratory Efficacy Trial Highlights
- Patient Criteria: Participants with advanced RP, agnostic to genotype, and characterized by severe vision loss, no- to limited vision.
- Safety and Efficacy: In addition to safety, exploratory efficacy endpoints include improvements in light sensitivity and visual function.

For further details, please check the press release below.
PR Newswire